Amongst the patients of advanced cancer with lymph node metastasis, those having a low hMLH1-IS had a significantly higher failure rate with the CMF regimen than those having a high hMLH1-IS (p = 0.03). Here, MLH1 is linked to metastatic malignant neoplasm in the lymph nodes.